Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 12 Feb 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 12 Dec 2017 Results assessing efficacy and tolerability, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 17 Oct 2017 Status changed from recruiting to active, no longer recruiting.